Calquence (acalabrutinib) — United Healthcare

Initial criteria

• Diagnosis of Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma
• AND one of the following: patient did not respond to primary therapy OR disease is relapsed or progressive

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Calquence therapy

Approval duration

12 months